Health-Related Quality of Life of Patients with Cervical Cancer According to the Duration of Treatment and Cancer Progression

Document Type : Research Articles


1 National Evidence-based Healthcare Collaborating Agency, City, Seoul, South Korea.

2 Center for Uterine cancer, Research Institute and Hospital, National Cancer Center, Gyeonggi-do, South Korea.

3 Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea.

4 Department of Obstetrics and Gynecology, Asan Medical Center, Seoul, South Korea.

5 Department of Obstetrics and Gynecology, Ewha Womans University Medical Center, Seoul, South Korea.

6 Department of Obstetrics and Gynecology, Chung-Ang University Hospital, Seoul, South Korea.

7 Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea.

8 College of Medicine, Inha University, Incheon, South Korea.


Objective: The purpose of this study was to assess health-related quality of life (HRQoL) in Korean patients with cervical cancer according to the duration of treatment and cancer progression of cervical cancer. Methods: This study included 452 outpatients with cervical intraepithelial neoplasia (CIN) or invasive cervical cancer from six tertiary hospitals in South Korea. The questionnaire included the EQ-5D-3L instrument, patients’ age, cancer progression (CIN or invasive cervical cancer), treatment duration (<1 year, ≥1 year but <2 years, and ≥2 years), treatment method (surgery, chemotherapy, radiation therapy), and presence of recurrence. HRQoL indices were calculated for these independent factors, and the mean was compared using ANOVA. Multiple regression analysis was performed to analyze factors affecting HRQoL in patients with cervical cancer. Results: The EQ-5D index was 0.93 for patients with CIN, 0.87 for patients with invasive cervical cancer, and 0.78 for patients with recurrent invasive cervical cancer. HRQoL was significantly lower as the CIN progresses to cervical cancer. HRQoL of patients with invasive cervical cancer was lowest within 1 year of treatment in all stages. In addition, the HRQoL of patients with CIN or invasive cervical cancer who received chemotherapy and radiotherapy was lower than that of patients who underwent surgery. Multiple regression analysis showed that the HRQoL decreased significantly as increasing age, the first year of treatment after diagnosis, cancer recurrence, or chemotherapy. Conclusion: The HRQoL of patients with cervical cancer is affected not only by the stage of cancer progression but also by the duration of treatment and the type of treatment. As a result, when trying to apply the quality of life of patients with cervical cancer to cost-utility analysis, it is necessary to consider the duration and the type of treatment they receive.


Main Subjects